Compare LEDS & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | AIMD |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 11.5M |
| IPO Year | 2010 | 2008 |
| Metric | LEDS | AIMD |
|---|---|---|
| Price | $1.92 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.8K | 32.5K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $43,009,000.00 | $124,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 729.81 | 498.95 |
| 52 Week Low | $1.01 | $1.26 |
| 52 Week High | $3.62 | $4.44 |
| Indicator | LEDS | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 44.44 |
| Support Level | $1.58 | $1.35 |
| Resistance Level | $2.17 | $1.65 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 10.64 | 46.43 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.